Use of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendations

Basit Öğe Kaydı
dc.authoridGogas Yavuz, Dilek/0000-0002-0075-6313
dc.authoridSahin, Ibrahim/0000-0002-6231-0034
dc.authoridBALCI, Mustafa Kemal/0000-0002-6494-3249
dc.authorwosidGogas Yavuz, Dilek/GRR-7277-2022
dc.authorwosidERBAS, AYSE TOMRIS/I-9256-2013
dc.authorwosidŞahin, İbrahim/HHY-8303-2022
dc.authorwosidSahin, Ibrahim/ABI-6050-2020
dc.authorwosidErbas, Tomris/AAF-7765-2019
dc.authorwosidGullu, Sevim/AAH-4136-2020
dc.authorwosidBALCI, Mustafa Kemal/C-2979-2016
dc.contributor.authorAkalin, Sema
dc.contributor.authorAydin, Hasan
dc.contributor.authorBalci, Mustafa Kemal
dc.contributor.authorComlekci, Abdurrahman
dc.contributor.authorDinccag, Nevin
dc.contributor.authorErbas, Tomris
dc.contributor.authorErsoz, Halil Onder
dc.date.accessioned2024-08-04T20:09:57Z
dc.date.available2024-08-04T20:09:57Z
dc.date.issued2018
dc.departmentİnönü Üniversitesien_US
dc.description.abstractThe goals of Type 2 diabetes treatment are to eliminate the hyperglycemia resulting from insulin insufficiency and/or insulin resistance, delay beta cell damage/depletion, and prevent other metabolic co-morbidities and complications. In the current treatment algorithms, lifestyle changes (medical nutrition therapy, physical exercise) and oral anti-diabetics are followed by insulin therapy, which is considered a replacement therapy for Type 2 diabetes. Pre-mixed insulin preparations, which are an option for patients with poor blood glucose level control under oral anti-diabetics treatment, have been developed to meet both basal and prandial insulin needs by simulating the physiological changes in insulin levels. The consensus on the necessity of individualizing insulin therapy requires physicians to have a detailed knowledge of the various uses of insulin. Therefore, this comprehensive consensus statement has been prepared by a panel of expert endocrinologists from different regions of Turkey to help physicians use biphasic insulin aspart 30 in suitable patients at the right time. In this statement, expert panel opinions on (a) Recommendations for the appropriate initiation, titration, and intensification of insulin treatment, and (b) The treatment algorithms in initiation, titration, and intensification of biphasic insulin aspart 30 treatment and special conditions specific to changing treatment regimen are presented.en_US
dc.description.sponsorshipNovo Nordisken_US
dc.description.sponsorshipThe meeting on which this consensus statement is based was funded by an independent grant from Novo Nordisk. Writing and editorial support were provided by KAPPA Consultancy Training Research Ltd., Istanbul, Turkey (supported by Novo Nordisk). The manuscript was edited for proper English language, grammar, punctuation, spelling, and overall style by native English speaking editors at American Journal Experts, Durham, North Carolina, USA (supported by Novo Nordisk). Authors declare that they have no conflict of interest. All authors contributed to the discussion and preparation of the consensus algorithms and critically revised and approved the manuscript, and the authors take full responsibility for the contents of the article.en_US
dc.identifier.doi10.25179/tjem.2017-57420
dc.identifier.endpage197en_US
dc.identifier.issn1301-2193
dc.identifier.issue3en_US
dc.identifier.scopus2-s2.0-85053229430en_US
dc.identifier.scopusqualityQ4en_US
dc.identifier.startpage183en_US
dc.identifier.trdizinid286954en_US
dc.identifier.urihttps://doi.org/10.25179/tjem.2017-57420
dc.identifier.urihttps://search.trdizin.gov.tr/yayin/detay/286954
dc.identifier.urihttps://hdl.handle.net/11616/92507
dc.identifier.volume22en_US
dc.identifier.wosWOS:000443340300007en_US
dc.identifier.wosqualityN/Aen_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakTR-Dizinen_US
dc.language.isoenen_US
dc.publisherAvesen_US
dc.relation.ispartofTurkish Journal of Endocrinology and Metabolismen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectBiphasic insulin aspart 30en_US
dc.subjectinsulin intensificationen_US
dc.subjectpremixed insulinen_US
dc.subjectinsulin analogen_US
dc.titleUse of Biphasic Insulin Aspart 30 in Type 2 Diabetes Treatment: Expert Panel Recommendationsen_US
dc.typeReview Articleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
TR-Dizin İndeksli Yayınlar Koleksiyonu